All patients
ECOG 0 HER2 negative
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer (BC), ribociclib based treatment vs. endocrine therapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MONALEESA-2, 2016 0.76 [0.63; 0.92]
MONALEESA-3, 2018 0.72 [0.57; 0.91]
0.74 [0.64 ; 0.87 ] MONALEESA-2, 2016, MONALEESA-3, 2018 2 0% 1,394 low not evaluable deaths (OS) (extension)detailed results MONALEESA-3, 2018 0.73 [0.59; 0.90]
0.73 [0.59 ; 0.90 ] MONALEESA-3, 2018 1 0% 726 NA not evaluable progression or deaths (PFS)detailed results MONALEESA-2, 2016 0.56 [0.43; 0.72]
MONALEESA-3, 2018 0.59 [0.48; 0.73]
MONALEESA-7, 2018 0.55 [0.44; 0.69]
0.57 [0.50 ; 0.65 ] MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018 3 0% 2,066 low not evaluable CBRdetailed results MONALEESA-2, 2016 1.46 [1.02; 2.10]
MONALEESA-3, 2018 1.40 [1.01; 1.94]
MONALEESA-7, 2018 1.64 [1.16; 2.33]
1.49 [1.22 ; 1.82 ] MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018 3 0% 2,066 low not evaluable objective responses (ORR)detailed results MONALEESA-2, 2016 1.81 [1.31; 2.50]
MONALEESA-3, 2018 1.75 [1.22; 2.52]
MONALEESA-7, 2018 1.64 [1.19; 2.26]
1.73 [1.43 ; 2.10 ] MONALEESA-2, 2016, MONALEESA-3, 2018, MONALEESA-7, 2018 3 0% 2,066 low not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 06:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 1379,1403,1381,1380